Company profile: Autobahn Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage restorative treatments for neuropsychiatric and neuroimmunologic disorders, including ABX-002 (CNS-directed TRβ agonist for major depressive disorder), ABX-003 (next-generation TRβ-selective thyromimetic in IND-enabling studies), ABX-101 (S1P receptor modulator with neuroinflammatory and neuroprotective benefits), and a brain-targeting chemistry platform for tailored CNS/peripheral drug exposure.
Products and services
- Brain-Targeting Chemistry Platform: A brain-targeting platform that creates small molecule prodrugs with tailored distribution profiles for CNS and peripheral drug exposure to tune central versus systemic delivery
- ABX-002: A CNS-directed thyroid hormone receptor beta agonist developed for treating multiple CNS disorders, initially focusing on major depressive disorder
- ABX-003: A next-generation, TRβ-selective thyromimetic engineered for enhanced brain distribution and CNS exposure, currently in IND-enabling studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Autobahn Therapeutics
Neural Therapeutics
HQ: Canada
Website
- Description: Provider of ethnobotanical drug discovery, psychedelic-based therapeutics for mental health, and dietary supplements. Focuses on San Pedro cactus for mescaline-derived compounds, conducts pharma and nutraceutical R&D leveraging indigenous knowledge, develops IP with partners like Validity Labs, and establishes sustainable, legally compliant sourcing and cultivation in Peru.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neural Therapeutics company profile →
Medfield Diagnostics
HQ: Sweden
Website
- Description: Provider of microwave-based medical devices and diagnostics, including the Medfield Strokefinder MD100 for assisting clinical evaluation and triage of suspected intracranial injuries in acute situations. Develops systems for screening brain injuries in prehospital and hospital settings and researches future microwave imaging applications beyond brain injuries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medfield Diagnostics company profile →
PhysioSonics
HQ: United States
Website
- Description: Provider of ultrasound imaging technology to monitor blood flow in the brain; development-stage device company based in Washington.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhysioSonics company profile →
Oryzon Genomics
HQ: Spain
Website
- Description: Provider of epigenetics-based therapeutics for cancer and CNS disorders, leveraging an epigenetic platform to identify biomarkers and targets and develop personalized therapies. Portfolio includes iadademstat (ORY-1001), an oral LSD1 inhibitor for leukemia and small cell lung cancer; vafidemstat (ORY-2001) for CNS disorders; ORY-4001, a selective HDAC6 inhibitor; and ORY-3001 for non-oncological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oryzon Genomics company profile →
CervoMed
HQ: United States
Website
- Description: Provider of clinical-stage research and development focused on discovering therapies for brain degenerative illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CervoMed company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Autobahn Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Autobahn Therapeutics
2.2 - Growth funds investing in similar companies to Autobahn Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Autobahn Therapeutics
4.2 - Public trading comparable groups for Autobahn Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →